EUVIMEDEUVIMED entdecken
Open Access

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [ 177 Lu]Lu-PSMA-617

Miguel Muniz, Oliver Sartor, Jacob J Orme, Regina M Koch, Hana R Rosenow, Ahmed M Mahmoud, Jack R Andrews, Adam M Kase, Irbaz B Riaz, Gokce Belge Bilgin, Matthew P Thorpe, A Tuba Kendi und 4 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.268277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Miguel Muniz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota; munizrincon.miguel@mayo.edu. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Liver Neoplasms, Lutetium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after treatment with [177Lu]Lu-PSMA-617 (LuPSMA) are scarce. The VISION trial reports a hazard ratio for overall survival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute duration of survival. Using real-world clinical data, we examined this important subgroup of patients, describing prostate-specific antigen (PSA) response and OS.

Methods

A single-institution database was assembled to include all patients receiving LuPSMA at Mayo Clinic in Rochester, Minnesota, for whom treatment was initiated between March 2022 and March 2023. Baseline clinicopathologic and imaging characteristics were abstracted. Patients were then categorized by presence or absence of liver metastasis on pretreatment prostate-specific membrane antigen (PSMA) PET. PSA response and OS for the 2 groups (liver metastasis vs. no liver metastasis) were compared using χ2 testing and the Kaplan-Meier method, respectively. A multivariate Cox regression analysis was performed, including established prognostic factors. Finally, those with pretreatment circulating tumor DNA as determined in an 83-gene panel were assessed for the presence of pathogenic and likely pathogenic alterations. These findings were summarized using descriptive statistics and compared between the 2 cohorts using the Fisher exact test.

Results

The overall cohort consisted of 273 patients, including 43 (15.75%) with liver metastasis on pretreatment PSMA PET/CT. The median number of cycles received was 3 (range, 1-6) for patients with liver metastasis and 5 (range, 1-6) for those without hepatic involvement. The 50% or greater reduction in PSA from baseline response rate was lower for those with liver metastasis than for those without (30.23% [13/43] vs 49.77% [106/213], P = 0.019). At a median follow-up of 10 mo (interquartile range, 9-13 mo), there was a significant difference in median OS (8.35 mo vs. not reached, P < 0.001). On multivariate analysis, the presence of liver metastasis was independently associated with shorter survival (hazard ratio, 4.06; P < 0.001).

Conclusion

Our data suggest that the presence of liver metastasis predicts poorer outcomes in patients receiving LuPSMA treatment. Alternative and combination approaches should be explored to maximize the antitumor activity of radiopharmaceutical therapy in the liver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingLiver NeoplasmsLutetiumDipeptidesHumansMaleAgedTreatment OutcomeMiddle AgedProstate-Specific AntigenRetrospective StudiesAged, 80 and over

Stichwörter der Autor:innen

LuPSMAPSMA-targeted radiopharmaceuticals[177Lu]Lu-PSMA-617liver metastasesmCRPCmetastatic castration-resistant prostate cancer

Substanzen

Heterocyclic Compounds, 1-RingLutetiumDipeptidesPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota; munizrincon.miguel@mayo.edu.
  • Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Department of Radiation Oncology, Kansas University Medical Center, Kansas City, Kansas.
  • Department of Urology, Mayo Clinic, Phoenix, Arizona.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Muniz, M., Sartor, O., Orme, J. J., Koch, R. M., Rosenow, H. R., Mahmoud, A. M., Andrews, J. R., Kase, A. M., Riaz, I. B., Belge Bilgin, G., Thorpe, M. P., Kendi, A. T., Johnson, G. B., Ravi, P., Kwon, E. D., & Childs, D. S. (2024). Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268277

Vancouver

Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, et al. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.268277

BibTeX
@article{Muniz2024,
  author = {Muniz, Miguel and Sartor, Oliver and Orme, Jacob J and Koch, Regina M and Rosenow, Hana R and Mahmoud, Ahmed M and Andrews, Jack R and Kase, Adam M and Riaz, Irbaz B and Belge Bilgin, Gokce and Thorpe, Matthew P and Kendi, A Tuba and Johnson, Geoffrey B and Ravi, Praful and Kwon, Eugene D and Childs, Daniel S},
  title = {Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [ 177 Lu]Lu-PSMA-617},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.268277}
}
Kostenlos starten →